Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) has signed an exclusive licence agreement with UWA, granting worldwide rights to a rapidly growing portfolio of selective serotonin-releasing agents. (See Appendix for Key Commercial Terms). These novel compounds, realised through a UWA–Emyria research partnership launched in 2021,2 include potential next-generation treatments…
Locksley Resources Limited (ASX:LKY) (“Locksley” or “the Company”) is pleased to announce high-grade antimony grades up to 46% Sb…
The World Gold Council (WGC) has released its latest Gold Demand Trends report, saying that total demand for the…
Cardiex Limited (ASX:CDX) (the “Company”) is pleased to report its activities during the September quarter 2024. Highlights: Manufacturing of…
Those interested in the lithium sector and investing in lithium stocks are often curious about which countries produce the…
The exorbitant cost of pharmaceutical drugs in the US has been a contentious issue for years, with the Republican…
Bitcoin, the most well-known cryptocurrency, paved the way for the cryptocurrency asset class. Now the cryptocurrency of choice, its…
In her view, it’s only a matter of time before both precious metals are squeezed higher. ‘We’ll see, but…
Platinum-group metals (PGMs) include platinum, palladium, rhodium and other metals, all of which are prized for their durability, resistance…